Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 116B 76.27M 67.08M 63.43M 57.53M 108M 7.32B 109M 759M 293M 3.74B 286M 280M 12B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 347B 228M 200M 189M 172M 323M 21.87B 325M 2.27B 876M 11.16B 855M 837M 35.86B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
Aug. 06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
May. 10 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
May. 07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Mar. 06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Nov. 05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-09 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-05-07 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
25-03-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-05 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-12 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-10 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day-4.64%
1 week-7.69%
Current month-10.56%
1 month-8.28%
3 months-10.00%
6 months-11.66%
Current year-27.09%
1 week 1,360
Extreme 1360
1,590
1 month 1,360
Extreme 1360
1,635
Current year 1,360
Extreme 1360
2,130
1 year 975
Extreme 975
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 2025-04-28
Corporate Officer/Principal - 2025-04-28
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-4.64%-7.69%+39.81%+187.43% 76.27M
+0.11%+1.71%+63.52%+117.61% 1,056B
+0.27%+0.92%+51.33%+73.35% 655B
+0.73%+0.68%+20.70%+74.90% 471B
-0.32%-2.69%+38.34%+41.47% 342B
+0.40%+4.64%+23.03%+29.82% 277B
+1.99%+0.44%+14.79%+14.65% 257B
+0.85%+6.35%+53.17%+54.39% 226B
+0.85%+1.10%+35.78%+101.82% 189B
+0.09%-2.30%-28.07%-60.73% 170B
Average -0.06%+0.02%+31.24%+63.47% 364.3B
Weighted average by Cap. +0.17%+1.04%+40.57%+69.99%

Financials

2024 2025
Net sales 91.79B 60.2M 52.95M 50.07M 45.41M 85.29M 5.78B 85.79M 600M 232M 2.95B 226M 221M 9.48B 127B 83.12M 73.1M 69.12M 62.7M 118M 7.98B 118M 828M 320M 4.07B 312M 305M 13.08B
Net income 23.85B 15.64M 13.75M 13.01M 11.8M 22.16M 1.5B 22.28M 156M 60.15M 766M 58.72M 57.44M 2.46B 3.09B 2.03M 1.78M 1.68M 1.53M 2.87M 194M 2.89M 20.17M 7.79M 99.2M 7.6M 7.44M 319M
Net Debt 134B 87.65M 77.09M 72.9M 66.12M 124M 8.41B 125M 873M 337M 4.29B 329M 322M 13.8B 231B 152M 133M 126M 114M 215M 14.55B 216M 1.51B 583M 7.42B 569M 557M 23.85B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
26-09-28 ARS 1,440.00 -4.64% 5,318
26-09-25 ARS 1,510.00 0.00% 2,196
26-09-24 ARS 1,510.00 -0.66% 10,447
26-09-23 ARS 1,520.00 -3.49% 7,769
26-09-22 ARS 1,575.00 +0.96% 349
  1. Stock Market
  2. Stocks
  3. RICH Stock